1、Q2 2025 Outlook Report April 2025 2 April 2025 Copyright 2025 Evaluate,a Norstella company.Contents About the Author.3 Executive Summary.3 Disclaimer.3 Outcomes of Biomedtrackers Large Impact Drug Catalysts from the Early 2025 Outlook Report.4 Drugs.6 VesiGel for Bladder Cancer.6 Pixclara for Brain

2、Cancer-Imaging.7 Reproxalap for Dry Eye(Ophthalmology).8 EB-101 for Epidermolysis Bullosa.9 Rinvoq for Giant Cell Arteritis.10 Sebetralstat for Hereditary Angioedema(HAE).11 SL-1009 for Metabolic-General.12 Nipocalimab for Myasthenia Gravis(MG).13 STS101 for Migraine and Other Headaches.14 NVK-002 f

3、or Myopic Macular Degeneration(MMD)/Pathological Myopia(Ophthalmology).15 Dovbleron for Non-Small Cell Lung Cancer(NSCLC).16 Defactinib for Ovarian Cancer.17 Clesrovimab for Respiratory Syncytial Virus(RSV)Prevention.18 Deals.19 Jazz Pharmaceuticals Acquisition of Chimerix Completed.19 3 April 2025

4、Copyright 2025 Pharma Intelligence UK Limited,a Citeline company(Unauthorized photocopying prohibited)About the Author Biomedtracker is an independent research service that offers proprietary clinical assessments and patient-based revenue forecasts of developmental drugs within a comprehensive and i

5、ntuitive drug information database.Clients from the pharmaceutical,biotech,and investment industries rely on Biomedtracker for its insight on the likelihood of approval,commercial potential,and future data and regulatory catalysts for drugs within the competitive landscape of every important disease

6、 and indication.Over the last several years,Biomedtracker has become the leader in providing objective information alongside evidence based clinical assessments and investment research on pipeline drugs worldwide.For more information on getting direct access to Biomedtracker,please email BiomedS.Exe